Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation

Toxicology and Applied Pharmacology

Volumn 278, Issue 1, 2014, Pages 72-77

  Nozaki, Yumiko ^a   Honda, Yayoi ^a   Tsujimoto, Shinji ^a   Watanabe, Hitoshi ^a   Kunimatsu, Takeshi ^a   Funabashi, Hitoshi ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Early afterdepolarization (EAD); Field potential duration (FPD); Human induced pluripotent stem cell derived cardiomyocytes (hiPS CMs); Multielectrode array (MEA); QT prolongation; Torsade de Pointes (TdP)

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; ASTEMIZOLE; CHROMANOL 293B; CISAPRIDE; CITALOPRAM; DILTIAZEM; NIFEDIPINE; PAROXETINE; TERFENADINE; TRIAMTERENE; VERAPAMIL;

ARTICLE; CLINICAL PRACTICE; ELECTRIC POTENTIAL; HEART MUSCLE CELL; HUMAN; PLURIPOTENT STEM CELL; QT INTERVAL; QT PROLONGATION; TORSADE DES POINTES;

EARLY AFTERDEPOLARIZATION (EAD); FIELD POTENTIAL DURATION (FPD); HUMAN INDUCED PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES (HIPS-CMS); MULTIELECTRODE ARRAY (MEA); QT PROLONGATION; TORSADE DE POINTES (TDP);

ACTION POTENTIALS; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LONG QT SYNDROME; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS; POTASSIUM CHANNEL BLOCKERS; RISK ASSESSMENT; TIME FACTORS; TORSADES DE POINTES; TOXICITY TESTS;

EID: 84899785990     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.04.007     Document Type: Article

References (20)

1. Asai Y., Tada M., Otsuji T.G., Nakatsuji N. Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development. Curr. Stem Cell Res. Ther. 2010, 5:227-232.
2. Boeck V., Overo K.F., Svendsen O. Studies on acute toxicity and drug levels of citalopram in the dog. Acta pharmacologica et toxicologica 1982, 50:169-174.
3. Braam S.R., Tertoolen L., van de Stolpe A., Meyer T., Passier R., Mummery C.L. Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes. Stem Cell Res. 2010, 4:107-116.
4. Egashira T., Yuasa S., Suzuki T., Aizawa Y., Yamakawa H., Matsuhashi T., Ohno Y., Tohyama S., Okata S., Seki T., et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc. Res. 2012, 95:419-429.
5. Fossa A.A., Gorczyca W., Wisialowski T., Yasgar A., Wang E., Crimin K., Volberg W., Zhou J. Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants. Journal of pharmacological and toxicological methods 2007, 55:78-85.
6. Guns P.J., Johnson D.M., Van Op den Bosch J., Weltens E., Lissens J. The electro-mechanical window in anaesthetized guinea pigs: a new marker in screening for Torsade de Pointes risk. Br. J. Pharmacol. 2012, 166:689-701.
7. Guo L., Qian J.Y., Abrams R., Tang H.M., Weiser T., Sanders M.J., Kolaja K.L. The electrophysiological effects of cardiac glycosides in human iPSC-derived cardiomyocytes and in guinea pig isolated hearts. Cell. Physiol. Biochem. 2011, 27:453-462.
8. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., Feldman O., Gepstein A., Arbel G., Hammerman H., et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229.
9. Mehta A., Chung Y., Sequiera G.L., Wong P., Liew R., Shim W. Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes. Toxicol. Sci. 2013, 131:458-469.
10. Merot J., Charpentier F., Poirier J.M., Coutris G., Weissenburger J. Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. Cardiovascular research 1999, 44:303-314.
11. Omata T., Kasai C., Hashimoto M., Hombo T., Yamamoto K. QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. Journal of pharmacological sciences 2005, 99:531-541.
12. Nagasawa Y., Chen J., Hashimoto K. Antiarrhythmic properties of a prior oral loading of amiodarone in in vivo canine coronary ligation/reperfusion-induced arrhythmia model: comparison with other class III antiarrhythmic drugs. Journal of pharmacological sciences 2005, 97:393-399.
13. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., Siegl P.K., Strang I., Sullivan A.T., Wallis R., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 2003, 58:32-45.
14. Smith D.H., Neutel J.M., Weber M.A. Comparisons of the effects of different long-acting delivery systems on the pharmacokinetics and pharmacodynamics of diltiazem. American journal of hypertension 1999, 12:1030-1037.
15. Tanaka T., Tohyama S., Murata M., Nomura F., Kaneko T., Chen H., Hattori F., Egashira T., Seki T., Ohno Y., et al. In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. Biochem. Biophys. Res. Commun. 2009, 385:497-502.
16. van Opstal J.M., Schoenmakers M., Verduyn S.C., de Groot S.H., Leunissen J.D., van Der Hulst F.F., Molenschot M.M., Wellens H.J., Vos M.A. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation 2001, 104:2722-2727.
17. Wenzel-Seifert K., Wittmann M., Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Deutsches Arzteblatt international 2011, 108:687-693.
18. Yamazaki K., Hihara T., Taniguchi T., Kohmura N., Yoshinaga T., Ito M., Sawada K. A novel method of selecting human embryonic stem cell-derived cardiomyocyte clusters for assessment of potential to influence QT interval. Toxicol. in Vitro 2012, 26:335-342.
19. Yokota S., Ishikura Y., Ono H. Cardiovascular effects of paroxetine, a newly developed antidepressant, in anesthetized dogs in comparison with those of imipramine, amitriptyline and clomipramine. Japanese journal of pharmacology 1987, 45:335-342.
20. Yoshida H., Sugiyama A., Satoh Y., Ishida Y., Yoneyama M., Kugiyama K., Hashimoto K. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ. J. 2002, 66:758-762.